1. Home
  2. STXS vs ELDN Comparison

STXS vs ELDN Comparison

Compare STXS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$2.45

Market Cap

210.0M

Sector

Health Care

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$1.52

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STXS
ELDN
Founded
1990
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.0M
123.1M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
STXS
ELDN
Price
$2.45
$1.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.00
$8.50
AVG Volume (30 Days)
414.9K
1.1M
Earning Date
11-11-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,075,000.00
N/A
Revenue This Year
$24.48
N/A
Revenue Next Year
$29.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.62
N/A
52 Week Low
$1.54
$1.35
52 Week High
$3.59
$4.98

Technical Indicators

Market Signals
Indicator
STXS
ELDN
Relative Strength Index (RSI) 51.47 36.14
Support Level $2.30 $1.55
Resistance Level $2.54 $1.69
Average True Range (ATR) 0.09 0.10
MACD 0.03 0.05
Stochastic Oscillator 61.86 2.04

Price Performance

Historical Comparison
STXS
ELDN

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: